Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Current Deferred Revenue: 2018-2024

Historic Current Deferred Revenue for Bicycle Therapeutics (BCYC) over the last 7 years, with Dec 2024 value amounting to $10.2 million.

  • Bicycle Therapeutics' Current Deferred Revenue rose 7.76% to $12.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.3 million, marking a year-over-year increase of 7.76%. This contributed to the annual value of $10.2 million for FY2024, which is 59.20% down from last year.
  • According to the latest figures from FY2024, Bicycle Therapeutics' Current Deferred Revenue is $10.2 million, which was down 59.20% from $25.0 million recorded in FY2023.
  • In the past 5 years, Bicycle Therapeutics' Current Deferred Revenue registered a high of $25.0 million during FY2023, and its lowest value of $10.1 million during FY2020.
  • In the last 3 years, Bicycle Therapeutics' Current Deferred Revenue had a median value of $20.4 million in 2022 and averaged $18.5 million.
  • As far as peak fluctuations go, Bicycle Therapeutics' Current Deferred Revenue surged by 1,292.17% in 2020, and later tumbled by 59.20% in 2024.
  • Yearly analysis of 5 years shows Bicycle Therapeutics' Current Deferred Revenue stood at $10.1 million in 2020, then spiked by 90.16% to $19.3 million in 2021, then rose by 5.94% to $20.4 million in 2022, then increased by 22.33% to $25.0 million in 2023, then crashed by 59.20% to $10.2 million in 2024.